
Genomic Testing
Latest News
Latest Videos

Shorts




More News

The prospective registry is evaluating a personalized counseling and monitoring strategy for patients who are at an increased risk of prostate cancer due to positive family history or pathogenic genetic variants.

Wesley Hauwei Chou, MD, outlined 2 projects evaluating potential biomarkers for treatment response in renal cell carcinoma.

Notable findings highlighted stark differences between this safety-net population and national averages.

The study is being conducted as part of the landmark ProtecT trial.

According to the authors, these findings support the early use of genomic testing to guide treatment decisions.

As the year comes to a close, we revisit some of this year’s top content on genomic testing.

Kenneth G. Nepple, MD, discusses a quality improvement initiative focused on identifying patients with prostate cancer who may be eligible for genetic testing.

The PROSTOX ultra test identifies men with localized prostate cancer who are at a higher risk of developing late GU toxicity from radiation, helping to inform treatment decisions.

Patients with GG1 disease and a high genomic classifier score had a significantly higher risk of disease progression.

Overall, germline pathogenic variants were common, identified in approximately 1 in 7 tested patients.

The approval is supported by data from the phase 3 AMPLITUDE trial.

The PROSTOX ultra test can predict which patients with localized prostate cancer are at a higher risk of GU toxicity from SBRT.

Veda N. Giri, MD, outlines alternative care delivery models that could help improve access to genetic testing for prostate cancer.


Veda N. Giri, MD, outlines some of the key barriers to genetic testing in prostate cancer.












